167 related articles for article (PubMed ID: 8946660)
1. Vancomycin serum concentrations in patients with renal dysfunction: a comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique.
Peckman HJ; Dupuis RE; Sawyer WT; Brouwer KL; Cross RE
Ther Drug Monit; 1996 Dec; 18(6):647-53. PubMed ID: 8946660
[TBL] [Abstract][Full Text] [Related]
2. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease.
Smith PF; Petros WP; Soucie MP; Copeland KR
Ther Drug Monit; 1998 Apr; 20(2):231-5. PubMed ID: 9558140
[TBL] [Abstract][Full Text] [Related]
3. Falsely elevated serum vancomycin concentrations in hemodialysis patients.
Follin SL; Mueller BA; Scott MK; Carfagna MA; Kraus MA
Am J Kidney Dis; 1996 Jan; 27(1):67-74. PubMed ID: 8546140
[TBL] [Abstract][Full Text] [Related]
4. Assay of vancomycin by fluorescence polarisation immunoassay and EMIT in patients with renal failure.
Saunders NJ; Want SV; Adams DJ
J Antimicrob Chemother; 1995 Aug; 36(2):411-5. PubMed ID: 8522471
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin assay performance in patients with acute renal failure.
Trujillo TN; Sowinski KM; Venezia RA; Scott MK; Mueller BA
Intensive Care Med; 1999 Nov; 25(11):1291-6. PubMed ID: 10654216
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence polarization immunoassay: can it result in an overestimation of vancomycin in patients not suffering from renal failure?
Sym D; Smith C; Meenan G; Lehrer M
Ther Drug Monit; 2001 Aug; 23(4):441-4. PubMed ID: 11477330
[TBL] [Abstract][Full Text] [Related]
7. Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay.
Morishige H; Shuto H; Ieiri I; Otsubo K; Oishi R
Ther Drug Monit; 1996 Feb; 18(1):80-5. PubMed ID: 8848826
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis.
Kingery JR; Sowinski KM; Kraus MA; Klaunig JE; Mueller BA
Pharmacotherapy; 2000 Jun; 20(6):653-6. PubMed ID: 10853620
[TBL] [Abstract][Full Text] [Related]
9. Interference with vancomycin fluorescence polarisation immunoassay in a nonuraemic patient.
Bowhay S; Timms P
Ther Drug Monit; 1997 Feb; 19(1):117-9. PubMed ID: 9029761
[TBL] [Abstract][Full Text] [Related]
10. Establishment of norvancomycin fluorescence polarization immunoassay for therapeutic drug monitoring.
Wu XJ; Zhang J; Yu JC; Cao GY; Shi YG; Zhang YY; Wang MG
J Antibiot (Tokyo); 2012 Jan; 65(1):35-9. PubMed ID: 22045420
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients.
Aubron C; Corallo CE; Nunn MO; Dooley MJ; Cheng AC
Ann Pharmacother; 2011 Oct; 45(10):1193-8. PubMed ID: 21896920
[TBL] [Abstract][Full Text] [Related]
12. Considerable lack of agreement between S-FPIA and EMIT cyclosporine assay in therapeutic drug monitoring, of heart transplant recipients.
Regazzi MB; Molinaro M; Tinelli C; D'Eril GM; Goggi C; Campana C; Fiorito V; Moratti R; Viganò M
Ther Drug Monit; 2000 Dec; 22(6):712-5. PubMed ID: 11128239
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of vancomycin serum concentrations in patients with renal failure.
Perino LM; Mueller BA
Ann Pharmacother; 1993; 27(7-8):892-3. PubMed ID: 8364273
[No Abstract] [Full Text] [Related]
14. Underestimation of rat serum vancomycin concentrations measured by an enzyme-multiplied immunoassay technique and the strategy for its avoidance.
Konishi H; Iga I; Nagai K
Drug Test Anal; 2014 Apr; 6(4):350-6. PubMed ID: 23943307
[TBL] [Abstract][Full Text] [Related]
15. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.
Somerville AL; Wright DH; Rotschafer JC
Pharmacotherapy; 1999 Jun; 19(6):702-7. PubMed ID: 10391415
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a new ultra-performance liquid chromatographic method for vancomycin assay in serum and its application to therapeutic drug monitoring.
Cao Y; Yu J; Chen Y; Zhang J; Wu X; Zhang Y; Li G
Ther Drug Monit; 2014 Apr; 36(2):175-81. PubMed ID: 24216537
[TBL] [Abstract][Full Text] [Related]
17. Precision and accuracy of commercial assays for vancomycin therapeutic drug monitoring: evaluation based on external quality assessment scheme.
Chen CY; Li MY; Ma LY; Zhai XY; Luo DH; Zhou Y; Liu ZM; Cui YM
J Antimicrob Chemother; 2020 Aug; 75(8):2110-2119. PubMed ID: 32464644
[TBL] [Abstract][Full Text] [Related]
18. The characteristics and impact indicator of vancomycin pharmacokinetics in cancer patients complicated with severe pneumonia.
Zhang X; Wang D
J Infect Chemother; 2020 May; 26(5):492-497. PubMed ID: 31983615
[TBL] [Abstract][Full Text] [Related]
19. Comparison of high-performance liquid chromatography with fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronic renal failure.
Najjar TA; al-Dhuwailie AA; Tekle A
J Chromatogr B Biomed Appl; 1995 Oct; 672(2):295-9. PubMed ID: 8581137
[TBL] [Abstract][Full Text] [Related]
20. Decreased vancomycin clearance in patients with congestive heart failure.
Shimamoto Y; Fukuda T; Tominari S; Fukumoto K; Ueno K; Dong M; Tanaka K; Shirasaka T; Komori K
Eur J Clin Pharmacol; 2013 Mar; 69(3):449-57. PubMed ID: 22791272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
